Barclays’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-124
| Closed | – | – | 7678 |
|
|
2017
Q4 | $0 | Hold |
124
| – | – | ﹤0.01% | 7411 |
|
|
2017
Q3 | $0 | Sell |
124
-100
| -45% | -$35 | ﹤0.01% | 7371 |
|
|
2017
Q2 | $0 | Sell |
224
-3,931
| -95% | -$2.85K | ﹤0.01% | 7317 |
|
|
2017
Q1 | $5K | Buy |
4,155
+4,116
| +10,554% | +$5.14K | ﹤0.01% | 6313 |
|
|
2016
Q4 | $0 | Sell |
39
-30
| -43% | -$52 | ﹤0.01% | 7171 |
|
|
2016
Q3 | $0 | Hold |
69
| – | – | ﹤0.01% | 7155 |
|
|
2016
Q2 | $0 | Sell |
69
-3,096
| -98% | -$5.94K | ﹤0.01% | 7044 |
|
|
2016
Q1 | $0 | Sell |
3,165
-6,627
| -68% | -$6.46K | ﹤0.01% | 6926 |
|
|
2015
Q4 | $10K | Sell |
9,792
-122,221
| -93% | -$392K | ﹤0.01% | 5424 |
|
|
2015
Q3 | $924K | Buy |
132,013
+114,534
| +655% | +$876K | ﹤0.01% | 2787 |
|
|
2015
Q2 | $122K | Sell |
17,479
-34,021
| -66% | -$265K | ﹤0.01% | 4534 |
|
|
2015
Q1 | $411K | Sell |
51,500
-77,185
| -60% | -$690K | ﹤0.01% | 3779 |
|
|
2014
Q4 | $1.16M | Sell |
128,685
-42,770
| -25% | -$365K | ﹤0.01% | 3077 |
|
|
2014
Q3 | $1.54M | Buy |
171,455
+28,808
| +20% | +$427K | ﹤0.01% | 2917 |
|
|
2014
Q2 | $2.42M | Buy |
142,647
+43,415
| +44% | +$708K | ﹤0.01% | 2403 |
|
|
2014
Q1 | $1.69M | Sell |
99,232
-151,269
| -60% | -$2.93M | ﹤0.01% | 2722 |
|
|
2013
Q4 | $4.51M | Sell |
250,501
-51,144
| -17% | -$966K | ﹤0.01% | 1919 |
|
|
2013
Q3 | $7.84M | Sell |
301,645
-124,953
| -29% | -$2.68M | 0.01% | 1334 |
|
|
2013
Q2 | $7.87M | Buy |
+426,598
| New | +$7.53M | 0.01% | 1271 |
|
Barclays's RPRX Position: Q1 2018 in Review
Barclays sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 124 shares.
Barclays first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $7.87M in Q2 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Barclays reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Barclays sold 124 Repros Therapeutics Inc. shares in Q1 2018.
- Barclays first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
- Barclays's Repros Therapeutics Inc. position peaked at $7.87M in Q2 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.